GlassScriptPhysician profile
Wesley Prichard
NPI 1194142166
$6,623.38
in general payments reported to CMS, 2019-2025
30 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $579 · 2021: $534 · 2022: $889 · 2023: $1,194 · 2024: $1,448 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,508 · Grant: $335 · Education: $51.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,507.50 |
| Grant | $335.00 |
| Education | $51.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,590.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $645.10 | 2020-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $584.68 | 2019-2025 | |
| Celgene Corporation | $444.95 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.96 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $348.92 | 2022-2024 | Dupixent |
| Pfizer INC. | $288.40 | 2019-2025 | |
| Janssen Biotech, INC. | $233.85 | 2020-2025 | Stelara, Simponi, Remicade |
| Genzyme Corporation | $172.54 | 2024-2025 | |
| Allergan, INC. | $115.42 | 2019 | |
| Janssen Scientific Affairs, LLC | $113.70 | 2020 | |
| Medtronic, INC. | $85.83 | 2023 | Pillcam, Barrx |
| Celltrion USA INC. | $82.80 | 2023-2025 | Vegzelma, Yuflyma |
| Phathom Pharmaceuticals, INC. | $56.00 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $51.42 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $51.00 | 2021 | |
| Lilly USA, LLC | $46.77 | 2024 | Omvoh |
| Ardelyx, INC. | $44.74 | 2022-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $43.05 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $41.03 | 2021-2022 | |
| Qol Medical, LLC | $33.22 | 2025 | Sucraid |
| Aimmune Therapeutics, INC. | $30.58 | 2024 | |
| Mylan Institutional INC. | $22.53 | 2023 | Hulio |
| Merck Sharp & Dohme LLC | $21.62 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $21.08 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $21.06 | 2022 | |
| Novo Nordisk INC | $16.52 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $14.10 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.60 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Prichard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.